Press Release NeuroDex Awarded Target ALS Biomarker Consortia Grant to Drive Advancements in ALS Research Natick, Massachusetts (November 6, 2024) – NeuroDex Inc. (“NeuroDex” or the “Company”) proudly announces its selection as a recipient of the Target ALS Biomarker Consortia Grant. This significant funding will bolster NeuroDex’s efforts to pioneer novel blood-based biomarkers, aiming to…
Imagine a future where the onset of Alzheimer’s or Parkinson’s disease could be predicted and effectively treated before symptoms even appear. Neurodegenerative diseases have long remained shrouded in a veil of uncertainty, with definitive diagnoses often coming too late to alter their devastating trajectories. Biomarkers are the beacons of hope in this landscape, potentially revolutionizing…
Introduction Leqembi® Arrives in China for Alzheimer’s Care Eisai, in partnership with BioArctic AB, has announced China’s approval of Leqembi® (乐意保), a groundbreaking treatment for mild cognitive impairment and mild dementia in Alzheimer’s disease. Following its success in the United States and Japan, this approval marks a significant stride in global healthcare. Understanding Alzheimer’s and…
Introduction Once thought to be mere cellular debris, exosomes have emerged as significant players in neurodegenerative diseases. These extracellular vesicles, ranging from 30 to 100 nm in size, are produced by all cell types in the central nervous system (CNS). Far from being simple waste disposal units, exosomes are involved in complex intercellular communication and…
In a groundbreaking move poised to reshape the landscape of brain disease treatments, CervoMed Inc. (formerly known as Diffusion Pharmaceuticals Inc.) has announced the successful completion of its merger with EIP Pharma Inc. This milestone marks the birth of a dynamic clinical-stage biotechnology company committed to advancing innovative therapies for degenerative diseases. The company’s press…